argenx’s Post

Not easy to start a new company

Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.

Our CEO, Dr. J. Jean Cui, connected with BiotechTV’s Brad Loncar following our completion of a $100 million financing to gain insight into Dr. Cui’s perspective on #precisionmedicines and how we are working to solve unmet medical needs by re-envisioning #cancer drug development. Watch the full video here: https://bit.ly/3Isffxy

Today's the day. Check out my presentation at Fierce Biotech JPM week on success factors for the biotech company journey from discovery to commercialization. You can register here. https://lnkd.in/eQTYR4nE

Thoughts on this? >> VC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech

Thoughts on this? >> VC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #productmarketing #biotech #healthcare

A crucial path towards meeting revenue goals and seeing marketable results is attracting the right investors, especially in the life science industry. Strong management, successful strategic plans, and key experience in the field have a common dividend: they're vital deciding factors for biotech investors. Interested in learning more? We've got that covered. Read the inside scoop with Bracken's Managing Partner Jim Gilligan here: https://lnkd.in/gFUNi67K #Biopharma #Investing #DueDiligence #Bracken

🌟 New Insights! 🌟 Don't miss Wilson Sonsini Goodrich & Rosati's latest Quarterly Life Sciences Report. This detailed analysis highlights the trends, key insights and developments in biotech and life sciences. LaunchBio's mission is to empower life sciences startups and foster an environment for innovation, and Wilson Sonsini's report is a great resource for anyone looking to stay informed about the current landscape and future directions in life sciences. Check it out below ⬇ #LifeSciences #Biotech #LaunchBio #WilsonSonsini #WSLifeSciReport

Afinum acquires a majority stake in evitria Abolon was mandated by Afinum Management GmbH, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria AG, which provides custom antibodies for research purposes. evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner. The transaction has been closed in December 2018. The enterprise value was not made publicly available. Abolon Group was exclusively mandated by Afinum.